The pull back is obvious that $0.116, $0.125 and $0.155 options...

The pull back is obvious that $0.116, $0.125 and $0.155 options are converted and immediately sold in the market but I reckon those are grabbed by LT investors. We shouldn't complain about investors taking profit what they thought is the right price to sell, however I feel they sold too early for our gain. Once this option saga is over, the SP is sure to bounce back as RSI and stochastic is showing signs of oversold condition.

I'm fully confident on the clinical efficacy outcome to be positive in March result which is only 10-12 weeks from today. Listening to Nina once we get commercial approval after March, the price of DXB200 $7000/m which eliminates the requirement of kidney transplant and suffering of two souls (donor and receptor). There is no alternative medication available atm, hence fast track approval or IND classification FDA can be granted in no time when phase3 Action trial still progresses. The recent recruitment of Mr Mark Diamond (former Pfizer) is strategically placed to succeed for commercialisation.

Once said, BUY when there is blood in the street, this applies to DXB. Not a buy or sell advice, DYOR.